Tag:
AstraZeneca
Latest Headlines
Latest Headlines
AstraZeneca pulling out all stops in R&D deal frenzy
In an interview with the Financial Times , AstraZeneca R&D chief Martin Mackay trotted out a roster of activities on his to-do list, ranging from in-licensing more programs, buying small biotechs, partnering with rivals and possibly coming up with a few risk-sharing arrangements with private equity.
First wave of AstraZeneca's CNS R&D group gets the ax
AstraZeneca isn't wasting any time in pushing ahead with draconian cuts to its neuroscience work in its big R&D hub south of Stockholm.
Buzz: Big Pharma suitors line up for a look at Amylin's books
One of the cardinal rules involved in deal-making focuses on the need to get as many buyers to the negotiating table as possible. The next big rule: Make sure everyone knows who's interested in bidding.
Clinical trials to size up antipsychotics like Seroquel for PTSD
The Army is trying to get a better handle on the very complicated issue of how drugs fit into the treatment of the many veterans diagnosed with post-traumatic stress disorder.
UPDATED: AstraZeneca leans on IT to transform an ailing business
In an effort to engineer a turnaround at the struggling giant, AstraZeneca ( $AZN ) has zeroed in on information technology projects that could deliver results. And Angela Yochem, the company's technology chief since last year, has been digging into the miscues at the global company.
Rebates cut $40B off drugmakers' returns
In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.
India's Cipla puts fire-sale prices on cancer drugs
Indian genericsmaker Cipla will sell its copies of cancer drugs for a fraction of their branded counterparts.
Pfizer, Lilly, AstraZeneca giving NIH abandoned drugs
Three of the world's largest drug manufacturers are going to empty out their closets and turn over research on unsuccessful drugs to the National Institutes of Health.
GSK's Witty has no interest in buying AstraZeneca
Thanks but no thanks. That was GlaxoSmithKline CEO Andrew Witty's comeback to the suggestion that maybe GSK should buy AstraZeneca.
GSK chief rules out AstraZeneca buyout
A buyout, he said, would be "very distracting".
